Mosaic Family Wealth Partners LLC Grows Position in Novo Nordisk A/S $NVO

Mosaic Family Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 406.4% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 19,911 shares of the company’s stock after purchasing an additional 15,979 shares during the period. Mosaic Family Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $732,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $25,000. WealthCollab LLC grew its stake in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $28,000. Maseco LLP purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO traded up $0.61 on Friday, hitting $49.49. 6,314,361 shares of the company’s stock traded hands, compared to its average volume of 10,696,942. The company’s 50 day simple moving average is $45.57 and its 200-day simple moving average is $45.87. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The firm has a market cap of $220.96 billion, a price-to-earnings ratio of 11.62, a P/E/G ratio of 4.46 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NVO shares. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Finally, HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday. Five research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.